US$ 20.62
tirzepatide or semaglutide for weight loss versus Once Weekly in Patients with Type 2 Diabetes Tirzepatide vs. Semaglutide: What's the
Description
20, November/December 1996, Pages 523-527

In dynamic compression, iFR offers some notable advantages over FFR: In FFR we are checking the average of the blood pressure and flow over the whole cardiac cycle systole and diastole

At 2.5mg, rounding from 16.7 to 17 units gives you approximately 2.55mg instead of 2.5mg

It is among the most actively studied investigational compounds in contemporary metabolic research literature
Conclusion GLP-1 receptor agonists remain among the most impactful therapies for type 2 diabetes and obesity management